Klarna, a leading global retail bank has signed an agreement to acquire PriceRunner. PriceRunner is a leading comparison shopping service in the Nordic region.

The company has more than 170 employees, businesses in Sweden, Denmark, Norway and the United Kingdom and compares 3.4 million products from 22,500 retailers in 25 countries. During the 12-month period ending on Sep 30, 2021, PriceRunner had revenues amounting to MSEK 460. PriceRunner will bring new features in the form of product reviews, rich product discovery and price comparisons to the Klarna app to enhance the shopping, payments and banking experience for consumers globally.

The transaction is subject to customary regulatory approvals.

Vinge’s team primarily consisted of Johan Larsson, Samra Baytar, Stina Bengtsson, Clara Sohlberg and Robin Fagerström (M&A), Sebastian Örndahl and Johan Wahlbom (Competition), Emma Stuart Beck and Henrik Schön (Financial Regulatory), Cecilia Möller Norsted and Anna-Karin Alin (Litigation), Martin Boström, Lisa Hörnqvist and Karl-Hugo Engdahl (IT/GDPR), Klara Secher and Rebecka Målquist (IP), Isabell Nielsen and Mario Saad (Commercial Agreements), Kamyar Najmi and Benjamin Vafaeian (Banking & Financing), Gustav Lindgren (Employment) and Tove Lövgren Frisk (Compliance).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025